| |
|
 |
Advanced
Targeting
Systems |
10451 Roselle Street, #300
San Diego, CA 92121 USA
Tollfree: (877) 889-2288
Phone: (858) 642-1988
Fax: (858) 642-1989 |
| |
|
Please continue to check back for more questions and answers.
If you have a question you'd like answered, just ask!
| By which mechanism is the SAP toxin cleaved? |
Targeting Trends, 14(2) |
| How can I target B-cells? |
Targeting Trends, 14(2) |
| Antagonists vs. Targeted Toxins | Targeting Trends, 13(3) |
| Lethal Dose of Saporin in Mice | Targeting Trends, 13(3) |
| Free gibberellic acid | Targeting Trends, 13(2) |
| OX7-SAP pan-neural toxin | Targeting Trends, 13(2) |
| Unconjugated antibody in custom conjuations | Targeting Trends, 13(2) |
| Chick-ZAP reducing agent | Targeting Trends, 13(2) |
| Blocking NGFr | Targeting Trends, 13(1) |
| Observe eliminated cells using fluorescence | Targeting Trends, 13(1) |
| Choosing the Secondary Conjugate | Targeting Trends, 12(4) |
| Mab-ZAP Binding and Activity | Targeting Trends, 12(3) |
| Custom Saporin Conjugates | Targeting Trends, 12(2) |
| Quinolinic Acid Antibody Conjugated to BSA | Targeting Trends, 12(2) |
| Mab-ZAP Assay Parameters | Targeting Trends, 12(2) |
| GAT1-SAP Lesions and Shipments | Targeting Trends, 12(1) |
| Hippocampal Neurons | Targeting Trends, 12(1) |
| Secondary Conjugates and Controls | Targeting Trends, 12(1) |
| Immunotoxin Tracers | Targeting Trends, 11(4) |
| Fab-ZAP Protocol and Toxicity | Targeting Trends, 11(3) |
| Testing Lots of Orexin-SAP | Targeting Trends, 11(2) |
| Lot-to-lot Variations | Targeting Trends, 11(1) |
| Monovalent or Bivalent | Targeting Trends, 11(1) |
| Detecting Cell Death | Targeting Trends, 11(1) |
| Anti-Melanopsin Protocol | Targeting Trends, 10(4) |
| Anti-Melanopsin Protocol | Targeting Trends, 10(3) |
| Somatostatin-14 and Somatostatin-28 | Targeting Trends, 10(2) |
| Conjugated or Unconjugated | Targeting Trends, 10(2) |
| Combining and Storing Aliquots | Targeting Trends, 10(2) |
| Immunogen for HRP-labeled Antibody to p53 | Targeting Trends, 10(2) |
| Anti-IgM-ZAP | Targeting Trends, 10(1) |
| Saporin Clearance | Targeting Trends, 9(4) |
| Apoptosis or Necrosis? | Targeting Trends, 9(3) |
| Cytotoxicity Assay Protocols | Targeting Trends, 9(2) |
| Secondary Conjugate Questions | Targeting Trends, 9(1) |
| Reducing Agents | Targeting Trends, 9(1) |
| Cost of Targeted Toxin | Targeting Trends, 8(4) |
| Targeted Toxin Dispoal | Targeting Trends, 8(3) |
| Intrastriatal Administration | Targeting Trends, 8(3) |
| p75 Receptor Activation | Targeting Trends, 8(3) |
| Sterilizing the Primary Antibody | Targeting Trends, 8(3) |
| Agonist Effects | Targeting Trends, 8(2) |
| Targeted Toxin Controls | Targeting Trends, 8(1) |
| Anti-DBH-SAP Administration | Targeting Trends, 7(4) |
| Retrograde Transport continued | Targeting Trends, 7(3) |
| Retrograde Transport | Targeting Trends, 7(2) |
| LPS Content | Targeting Trends, 7(1) |
| Dose Ranging | Targeting Trends, 6(4) |
| Saporin Safety | Targeting Trends, 6(3) |
| Cytotoxicity of Unbound Saporin | Targeting Trends, 6(2) |
| Effective Toxins continued | Targeting Trends, 6(1) |
| Effective Toxins | Targeting Trends, 5(4) |
| Eliminating CBF Neurons | Targeting Trends, 5(3) |
| Streptavidin versus Avidin | Targeting Trends, 5(2) |
| Not the Right Stuff | Targeting Trends, 5(1) |
| Dosing, Volume, and Animal Care | Targeting Trends, 4(3) |
| Retrograde Transport | Targeting Trends, 4(2) |
| Custom Peptide-Saporin Conjugates | Targeting Trends, 4(1) |
| Custom Antibody-Saporin Conjugates | Targeting Trends, 3(4) |
| Neuropeptide Toxins | Targeting Trends, 3(3) |
| Toxin Safety | Targeting Trends, 3(1) |
| Time Course of Targeted Toxins | Targeting Trends, 2(4) |
| In Vivo Delivery of Targeted Toxins |
Targeting Trends, 2(3) |
| Suicide Transport and Immunolesioning | Targeting Trends, 2(2) |
| In Vivo Use of Targeted Toxins |
Targeting Trends, 2(1) |
| Second Immunotoxins | Targeting Trends, 1(4) |
|
